Financials Cytokinetics, Incorporated

Stocks

CYTK

US23282W6057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/06/2026 BST			5-day change	1st Jan Change
67.90 ^USD	-5.01%		-7.84%	+6.86%

06-02	Cytokinetics Insider Sold Shares Worth $1,111,200, According to a Recent SEC Filing	MT
06-01	Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy	RE

Projected Income Statement: Cytokinetics, Incorporated

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	70.43	94.59	7.53	18.47	88.04	109.3	387.4	847.4
Change	-	34.3%	-92.04%	145.34%	376.56%	24.12%	254.51%	118.77%
EBITDA ¹	-184	-318.4	-484.3	-526.7	-602.1	-732.4	-544.6	-336
Change	-	-73%	-52.11%	-8.76%	-14.32%	-21.63%	25.63%	38.3%
EBIT ¹	-186.3	-324.2	-496.2	-536.2	-612.3	-752.4	-573.7	-217.2
Change	-	-74.01%	-53.05%	-8.07%	-14.17%	-22.89%	23.76%	62.14%
Interest Paid ¹	-16.44	-19.41	-28.31	-37.7	-45.58	-59.65	-65.36	-78.49
Earnings before Tax (EBT) ¹	-215.3	-389	-526.2	-589.5	-785	-839.8	-661.5	-341.8
Change	-	-80.65%	-35.3%	-12.03%	-33.15%	-6.99%	21.24%	48.32%
Net income ¹	-215.3	-389	-526.2	-589.5	-785	-806	-652.8	-319.1
Change	-	-80.65%	-35.3%	-12.03%	-33.15%	-2.68%	19%	51.11%
Announcement Date	24/02/22	01/03/23	27/02/24	27/02/25	24/02/26	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4
Net sales ¹	2.843	5.437	55.6	1.148	88.97	2.515	1.957	4.613	0.867	0.378	1.672	0.835	0.249	0.463	16.93	1.579	66.77	1.936	17.76	19.36	17.26	26.95	42	55.87	80.63	109	153.8
Change	-	91.24%	922.62%	-97.94%	7,649.83%	-97.17%	-22.19%	135.72%	-81.21%	-56.4%	342.33%	-50.06%	-70.18%	85.94%	3,555.94%	-90.67%	4,128.56%	-97.1%	817.1%	9.01%	-10.85%	56.17%	55.87%	33.01%	44.33%	35.18%	41.06%
EBITDA ¹	-54.25	-68.74	-20.97	-76.52	-9.467	-107	-125.4	-122.6	-120.2	-120.4	-121.1	-123.9	-127.8	-138.4	-136.7	-153.3	-109.2	-164.1	-175.5	-180.2	-185.2	-201	-199.2	-178.3	-	-	-
Change	-	-26.7%	69.49%	-264.88%	87.63%	-1,030.59%	-17.13%	2.19%	1.98%	-0.18%	-0.56%	-2.33%	-3.12%	-8.32%	1.25%	-12.2%	28.77%	-50.22%	-6.97%	-2.7%	-2.75%	-8.56%	0.91%	10.48%	-	-	-
EBIT ¹	-54.8	-69.2	-21.7	-77.86	-10.87	-108.4	-127	-124.5	-122	-122.3	-127.4	-126.2	-130.2	-140.8	-139	-155.6	-111.5	-166.8	-178.4	-183.6	-194.6	-193	-185.8	-176.9	-155.7	-138.8	-101.2
Change	-	-26.29%	68.64%	-258.72%	86.03%	-897.25%	-17.14%	2.01%	1.95%	-0.18%	-4.21%	0.93%	-3.12%	-8.17%	1.25%	-11.93%	28.35%	-49.55%	-6.96%	-2.94%	-5.97%	0.82%	3.71%	4.79%	12.01%	10.85%	27.05%
Charge d'intérêts ¹	-4.073	-4.161	-4.218	-2.746	-2.807	-6.804	-7.057	-6.961	-7.045	-7.136	-7.164	-7.103	-12.73	-8.928	-8.938	-8.868	-11.08	-11.35	-14.27	-14.52	-14.61	-15.16	-15.48	-20.26	-20.46	-21.49	-22.56
Earnings before Tax (EBT) ¹	-61.55	-76.09	-30.57	-89.44	-19.82	-142.3	-137.4	-131.3	-128.6	-129.4	-136.9	-135.6	-143.3	-160.5	-150	-161.4	-134.4	-306.2	-183	-206	-216.4	-215.7	-209.7	-201.5	-182.3	-165	-126.6
Change	-	-23.61%	59.82%	-192.59%	77.84%	-618.01%	3.46%	4.43%	2.02%	-0.61%	-5.77%	0.92%	-5.66%	-12.02%	6.56%	-7.57%	16.73%	-127.86%	40.22%	-12.57%	-5.04%	0.32%	2.79%	3.89%	9.54%	9.49%	23.28%
Net income ¹	-61.55	-76.09	-30.57	-89.44	-19.82	-142.3	-137.4	-131.3	-128.6	-129.4	-136.9	-135.6	-143.3	-160.5	-150	-161.4	-134.4	-306.2	-183	-206	-215.5	-214.4	-209.1	-201.5	-182.3	-165	-126.6
Change	-	-23.61%	59.82%	-192.59%	77.84%	-618.01%	3.46%	4.43%	2.02%	-0.61%	-5.77%	0.92%	-5.66%	-12.02%	6.56%	-7.57%	16.73%	-127.86%	40.22%	-12.57%	-4.6%	0.51%	2.48%	3.61%	9.54%	9.49%	23.28%
Announcement Date	05/08/21	03/11/21	24/02/22	04/05/22	04/08/22	03/11/22	01/03/23	04/05/23	03/08/23	02/11/23	27/02/24	08/05/24	08/08/24	06/11/24	27/02/25	06/05/25	07/08/25	05/11/25	24/02/26	05/05/26	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Cytokinetics, Incorporated

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt ¹	-329	-173	-7.45	-408	-29	-583	-601	-1,335
Change	-	47.42%	95.69%	-5,376.51%	92.89%	-1,909.86%	-3.09%	-122.13%
Announcement Date	24/02/22	01/03/23	27/02/24	27/02/25	24/02/26	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Cytokinetics, Incorporated

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
CAPEX ¹	48.87	11.34	1.416	3.906	24.81	15.32	22.76	49.94
Change	-	-76.81%	-87.51%	175.85%	535.1%	-38.26%	48.6%	119.43%
Free Cash Flow (FCF) ¹	-191.4	-310.9	-415.7	-399.8	-534.8	-661.4	-553	-256.6
Change	-	-62.41%	-33.75%	3.84%	-33.77%	-23.66%	16.38%	53.59%
Announcement Date	24/02/22	01/03/23	27/02/24	27/02/25	24/02/26	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Cytokinetics, Incorporated

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-261.31%	-336.61%	-6,431.78%	-2,851.13%	-683.94%	-670.24%	-140.6%	-39.65%
EBIT Margin (%)	-264.54%	-342.75%	-6,589.71%	-2,902.72%	-695.44%	-688.59%	-148.09%	-25.63%
EBT Margin (%)	-305.72%	-411.21%	-6,988.63%	-3,191.11%	-891.6%	-768.55%	-170.75%	-40.34%
Net margin (%)	-305.72%	-411.21%	-6,988.63%	-3,191.11%	-891.6%	-737.58%	-168.53%	-37.66%
FCF margin (%)	-271.76%	-328.64%	-5,521.24%	-2,164.1%	-607.48%	-605.24%	-142.75%	-30.28%
FCF / Net Income (%)	88.89%	79.92%	79%	67.82%	68.13%	82.06%	84.71%	80.41%
Profitability
ROA	-31.32%	-41.91%	-57.23%	-52.97%	-55.55%	-47.8%	-27.6%	0.86%
ROE	-120.54%	-572.15%	-	-	-	-	-	-27.39%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	69.39%	11.98%	18.8%	21.14%	28.18%	14.02%	5.88%	5.89%
CAPEX / EBITDA (%)	-26.56%	-3.56%	-0.29%	-0.74%	-4.12%	-2.09%	-4.18%	-14.86%
CAPEX / FCF (%)	-25.53%	-3.65%	-0.34%	-0.98%	-4.64%	-2.32%	-4.12%	-19.46%
Items per share
Cash flow per share ¹	-	-3.334	-4.292	-3.535	-4.246	-2.948	-1.166	-
Change	-	-	-28.73%	17.64%	-20.11%	30.58%	60.44%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	2.876	-1.138	-3.801	-1.145	-5.365	-1.56	-0.521	4.643
Change	-	-139.56%	-234.07%	69.87%	-368.5%	70.92%	66.61%	991.16%
EPS ¹	-2.8	-4.33	-5.45	-5.26	-6.54	-6.464	-4.654	-1.999
Change	-	-54.64%	-25.87%	3.49%	-24.33%	1.16%	28.01%	57.04%
Nbr of stocks (in thousands)	83,883	94,631	98,054	118,014	122,265	135,771	135,771	135,771
Announcement Date	24/02/22	01/03/23	27/02/24	27/02/25	24/02/26	-	-	-